-
公开(公告)号：US11413353B2
公开(公告)日：2022-08-16
申请号：US15779446
申请日：2016-11-23
发明人： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
摘要： In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
-
公开(公告)号：US20190381185A1
公开(公告)日：2019-12-19
申请号：US15779450
申请日：2016-11-23
发明人： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
摘要： In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
-
公开(公告)号：US11707533B2
公开(公告)日：2023-07-25
申请号：US16940326
申请日：2020-07-27
发明人： Yun-Hee Park , Ho Young Song , Hyun Min Ryu , Sung Min Kim , Ju Yuel Baek , Ji Hye Oh , Nara Han , Hyoung Rae Kim , Kyung Eun Park , Hyeun Joung Lee , Ju Young Lee , Dae Hyuck Kang , Young-Jae Yang , Ji-Na You , Yong Zu Kim , Chang Sun Lee , Jeiwook Chae , Jinwon Jung , Juhee Kim , Bora Lee , Daehae Song , Byungje Sung , Donghoon Yeom , Jaehyun Eom , Youngeun Hong , Jinhyung Ahn , Yangsoon Lee , Kyungjin Park , Jiseon Yoo , Minji Park
CPC分类号： A61K47/6849 , A61K47/6803 , A61P35/00 , C07K16/2803
摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
-
公开(公告)号：US11173214B2
公开(公告)日：2021-11-16
申请号：US15779444
申请日：2016-11-23
发明人： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
摘要： The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.
-
公开(公告)号：US11975076B2
公开(公告)日：2024-05-07
申请号：US17525582
申请日：2021-11-12
发明人： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
CPC分类号： A61K47/6889 , A61K47/60 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6855 , A61K47/6883 , A61P35/00
摘要： The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.
-
公开(公告)号：US20230405139A1
公开(公告)日：2023-12-21
申请号：US18209299
申请日：2023-06-13
发明人： Yun-Hee Park , Ho Young Song , Hyun Min Ryu , Sung Min Kim , Ju Yuel Baek , Ji Hye Oh , Nara Han , Hyoung Rae Kim , Kyung Eun Park , Hyeun Joung Lee , Ju Young Lee , Dae Hyuck Kang , Young-Jae Yang , Ji-na You , Yong Zu Kim , Chang Sun Lee , Jeiwook Chae , Jinwon Jung , Juhee Kim , Bora Lee , Daehae Song , Byungje Sung , Donghoon Yeom , Jaehyun Eom , Youngeun Hong , Jinhyung Ahn , Yangsoon Lee , Kyungjin Park , Jiseon Yoo , Minji Park
CPC分类号： A61K47/6849 , A61P35/00 , A61K47/6803 , C07K16/2803
摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20230270868A1
公开(公告)日：2023-08-31
申请号：US18113948
申请日：2023-02-24
发明人： Ho Young Song , Sung Min Kim , Hyoungrae Kim , Kyung Eun Park , Chul-Woong Chung , Yun-Hee Park , Hyo Jung Choi , Su In Lee , Juyuel Baek , Hyeun Joung Lee , Ju Young Lee , Ji Hye Oh , Jeiwook Chae , Yeong Soo Oh , Yong Zu Kim
CPC分类号： A61K47/552 , A61P35/00
摘要： The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.
-
公开(公告)号：US11654197B2
公开(公告)日：2023-05-23
申请号：US16328256
申请日：2018-03-29
发明人： Ho Young Song , Sung Min Kim , Hyoungrae Kim , Kyung Eun Park , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Su In Lee , Juyuel Baek , Hyeun Joung Lee , Ju Young Lee , Ji Hye Oh , Jeiwook Chae , Yeong Soo Oh , Yong Zu Kim
CPC分类号： A61K47/552 , A61P35/00
摘要： The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
-
公开(公告)号：US20220218840A1
公开(公告)日：2022-07-14
申请号：US17525582
申请日：2021-11-12
发明人： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
摘要： The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.
-
公开(公告)号：US11167040B2
公开(公告)日：2021-11-09
申请号：US15779450
申请日：2016-11-23
发明人： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
摘要： In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.016 秒)
